This randomized phase I trial studies the side effects of vaccine therapy in preventing
cytomegalovirus (CMV) infection in patients with hematological malignancies undergoing donor
stem cell transplant. Vaccines made from a tetanus-CMV peptide or antigen may help the body
build an effective immune response and prevent or delay the recurrence of CMV infection in
patients undergoing donor stem cell transplant for hematological malignancies.